Guide · Updated April 2026

Do GLP-1s Affect Fertility? The Ozempic Baby Phenomenon

GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are linked to unexpected pregnancies, especially in women with PCOS. Clinical trial data shows 53 pregnancies among 9,736 female semaglutide participants. About 2.2% of women conceived within six months of starting treatment. The primary mechanism is weight loss restoring ovulation, not a direct fertility drug effect.

The term “Ozempic babies” started trending in late 2024, and it has not slowed down. Women on GLP-1 medications for weight loss or diabetes are reporting unexpected pregnancies at rates that caught even their doctors off guard. A Cleveland Clinic OB/GYN called it “not an overstatement to say we’re seeing an Ozempic baby boom.”

But here is the thing: no GLP-1 fertility study was ever designed to test this. Semaglutide and tirzepatide are GLP-1 receptor agonists that slow gastric emptying, reduce appetite, and improve insulin sensitivity. They were built for blood sugar control and weight loss, not reproduction. The fertility connection is a side effect of the weight loss itself, and for women with conditions like PCOS, that side effect can be life-changing.

I have been on Mounjaro for over a year tracking my body composition with DEXA scans, so I follow the research closely. This guide covers what the data actually says, what the FDA recommends, and what you should know about contraception if you are on a GLP-1.

How GLP-1 Medications Can Restore Fertility

The connection between GLP-1 fertility and unexpected pregnancies is not magic. It comes down to biology.

Weight Loss and Ovulation

This is the biggest factor. Even a 5-10% body weight reduction can restart regular ovulation in women who had stopped ovulating due to excess weight. In the STEP 1 trial (NEJM, 2021), semaglutide 2.4 mg produced an average weight loss of 14.9% over 68 weeks. The SURMOUNT-1 trial (NEJM, 2022) showed tirzepatide at 15 mg producing 22.5% weight loss. Both well above the threshold needed to restore ovulatory cycles.

Each BMI point above 29 decreases female fertility by roughly 5%, according to Cleveland Clinic data. A woman who loses 30-50 pounds on a GLP-1 could see her fertility shift dramatically, sometimes within the first few months of treatment.

Insulin Resistance and Hormones

GLP-1s improve insulin sensitivity directly, not just through weight loss. High insulin levels drive excess testosterone production in the ovaries, which suppresses ovulation. By reducing insulin, GLP-1 medications lower androgen levels and allow normal ovulatory cycles to resume.

This is especially relevant for women with PCOS, the leading cause of anovulatory infertility, which affects about 10% of women of reproductive age.

Direct Hormonal Effects

Early research suggests GLP-1 receptor agonists may reduce luteinizing hormone (LH) and androgen levels beyond what weight loss alone would explain. Mouse studies show GLP-1 RA exposure may reduce ovarian inflammation. Combined metformin and semaglutide therapy outperformed metformin alone for both metabolic and reproductive outcomes in recent studies.

The PCOS Connection: Why It Matters Most

PCOS is at the center of the Ozempic baby phenomenon. The condition creates a vicious cycle: obesity worsens insulin resistance, high insulin drives androgen production, and excess androgens suppress ovulation.

GLP-1 medications break this cycle at multiple points:

• Weight loss of 10-15% (typical on semaglutide or tirzepatide)
• Improved insulin sensitivity reducing compensatory hyperinsulinemia
• Reduced androgen levels allowing follicular development
• Restored ovulatory cycles in women who had not ovulated in months or years

A meta-analysis of 11 randomized controlled trials (840 patients, published in BMC Endocrine Disorders, 2023) found that GLP-1 RA usage was associated with improved natural pregnancy rates in women with PCOS. In one trial of 176 overweight women with PCOS, the pregnancy rate with exenatide (an older GLP-1) was 43.6% versus 18.7% with metformin during the second treatment period.

GLP-1 prescribing among women with PCOS increased from 2.4% in 2021 to 17.6% in 2025, a sevenfold increase according to Truveta data. That rapid adoption means more women with suppressed fertility are suddenly ovulating again, often without realizing it.

Among patients who lost more than 5% body weight, 71% achieved normal menstrual cycles. If you have PCOS and start a GLP-1, your contraception plan needs to change before your next injection.

What the Clinical Data Shows

No large-scale trial has been designed to study GLP-1 fertility effects directly. But we have useful data from pregnancies that occurred during clinical trials and from population-level analyses.

The reassuring finding across all studies: accidental first-trimester exposure does not appear to increase the risk of major birth defects. The Dao 2024 study found a 2.6% rate of major birth defects in GLP-1 exposed pregnancies, virtually identical to the 2.3% background rate.

That said, these are small sample sizes. No one is claiming GLP-1 medications are safe during pregnancy. The FDA has not approved any GLP-1 for use during pregnancy, and the recommendation is clear: stop the medication as soon as you know you are pregnant.

GLP-1 Medications and Birth Control: A Real Problem

This is where things get practical, and where the distinction between semaglutide and tirzepatide matters.

Tirzepatide (Mounjaro/Zepbound): Confirmed Interaction

The FDA label for tirzepatide includes a specific warning: it may reduce the effectiveness of oral hormonal contraceptives. Tirzepatide slows gastric emptying significantly, which can reduce absorption of oral medications including birth control pills.

The FDA recommends:

• Switch to a non-oral contraceptive method (IUD, implant, injection, patch), OR
• Add a barrier method (condoms) for 4 weeks after starting tirzepatide and 4 weeks after each dose increase

This is not theoretical. If you are on Mounjaro or Zepbound and relying solely on the pill, you may not be fully protected.

Semaglutide (Ozempic/Wegovy): No Confirmed Interaction

Current evidence does not show semaglutide reduces oral contraceptive bioavailability. The UK’s Faculty of Sexual and Reproductive Healthcare (FSRH) does not recommend additional barrier methods specifically for semaglutide.

But the GI side effects still matter. If you vomit within 3 hours of taking your pill, that dose may not have absorbed. If you are experiencing persistent nausea, vomiting, or diarrhea (which the side effects guide covers in detail), your oral contraceptive reliability drops regardless of which GLP-1 you are on.

What Actually Works

If you are starting a GLP-1 and do not want to get pregnant, talk to your doctor about switching to a non-oral method. This is the single most actionable piece of advice in this entire article.

When to Stop GLP-1s Before Trying to Conceive

If you are planning a pregnancy, timing your GLP-1 discontinuation matters.

Semaglutide: The FDA recommends stopping at least 2 months before attempting conception. Semaglutide has a half-life of about 1 week, and it takes roughly 5-7 weeks (five half-lives) for the drug to fully clear your system.

Tirzepatide: The FDA label does not specify a washout period, but UK prescribing guidance recommends at least 1 month. Tirzepatide has a shorter half-life of about 5 days.

The Endocrine Society recommends a 2-month washout for semaglutide based on pharmacokinetics. If you are working with a fertility specialist, they may have more specific guidance based on your situation.

What about the weight you have lost? The good news is that the metabolic benefits of weight loss do not disappear overnight. Many women maintain improved ovulation for months after stopping, especially if they keep up the lifestyle changes. Our maintenance guide covers strategies for holding onto your progress after stopping.

Animal Studies: What They Show (and Don’t)

The FDA labels for both semaglutide and tirzepatide reference animal reproduction studies showing concerning results: decreased fetal weight, delayed bone development, skeletal variations, and increased fetal mortality in mice and rats.

But context matters. Researchers attributed these effects primarily to reduced maternal food intake and weight loss during pregnancy, not to direct toxicity from the GLP-1 medication itself. Placental transfer of GLP-1 agonists is minimal. One study showed fetal-to-maternal concentration ratios of 0.017 or less for exendin-4.

This does not mean GLP-1s are safe during pregnancy. It means the risk is likely from caloric restriction (which any appetite-suppressing drug would cause) rather than the molecule itself. Still, no one should stay on a GLP-1 during pregnancy.

If You Get Pregnant on a GLP-1: What to Do

First: do not panic. The data we have (Dao 2024, Parker 2025, Morton 2025) consistently shows no increased rate of major birth defects from accidental first-trimester exposure.

Steps to take:

1. Stop the GLP-1 medication immediately. Do not wait for your next scheduled dose.
2. Contact your prescriber. Let them know when your last dose was and when you estimate conception occurred.
3. See your OB/GYN. Standard prenatal care applies. There is no special monitoring protocol for GLP-1 exposure, but your doctor should be aware.
4. Do not restart until after delivery and, if breastfeeding, until after you have weaned (GLP-1s are not studied in breastfeeding).

The Danish nationwide cohort study (Human Reproduction Open, 2026) of 529 GLP-1 exposed pregnancies found that preterm birth risk was only elevated in women with pre-existing diabetes, not in those using GLP-1s for weight management.

GLP-1 Fertility and Men

Most of the Ozempic baby conversation focuses on women, but men are not excluded. Obesity is linked to lower testosterone, reduced sperm quality, and erectile dysfunction. Weight loss from GLP-1 medications can improve all three.

A man losing 15-20% body weight on tirzepatide may see testosterone levels rise, sperm parameters improve, and sexual function recover. If you and your partner are both on GLP-1 medications, the fertility boost could be coming from both sides.

That said, there is limited direct research on GLP-1 medications and male fertility specifically. The improvements are most likely driven by weight loss and improved body composition rather than the medication acting on reproductive hormones directly.

The Bottom Line

GLP-1 medications are not fertility drugs, but they can restore fertility that obesity and PCOS had suppressed. The Ozempic baby phenomenon is real, driven primarily by weight loss restarting ovulation. If you are on a GLP-1 and do not want to get pregnant, switch to a non-oral contraceptive (especially on tirzepatide). If you are trying to conceive, work with your doctor to time your GLP-1 washout at least 2 months before trying. And if you get pregnant unexpectedly, the current data is reassuring: stop the medication and proceed with normal prenatal care.

For help finding an affordable GLP-1 provider, check our provider comparison directory or start with the cheapest GLP-1 options guide.

FAQ

Can Ozempic help you get pregnant?

Ozempic (semaglutide) is not a fertility medication and is not FDA-approved for that purpose. However, the weight loss it produces can restore ovulation in women whose fertility was suppressed by obesity or PCOS. About 2.2% of women became pregnant within six months of starting GLP-1 treatment in population-level data.

Should I stop Ozempic or Mounjaro before trying to conceive?

Yes. The FDA recommends stopping semaglutide (Ozempic, Wegovy) at least 2 months before attempting pregnancy. For tirzepatide (Mounjaro, Zepbound), UK guidance recommends at least 1 month. Talk to your doctor about timing based on your specific situation.

Does Mounjaro interfere with birth control pills?

Yes. Tirzepatide (the active ingredient in Mounjaro and Zepbound) can reduce oral contraceptive absorption by slowing gastric emptying. The FDA recommends switching to a non-oral contraceptive or adding a barrier method for 4 weeks after starting and after each dose increase.

Is it safe if I got pregnant while on a GLP-1?

Current data from multiple studies (Dao 2024, Parker 2025, Morton 2025) shows no increased rate of major birth defects from accidental first-trimester GLP-1 exposure. Stop the medication immediately and contact your healthcare provider. The birth defect rate in exposed pregnancies (2.6%) is nearly identical to the background rate (2.3%).

Do GLP-1 medications affect male fertility?

There is limited direct research, but weight loss from GLP-1 medications can improve testosterone levels, sperm quality, and sexual function in men with obesity. These improvements are most likely driven by the weight loss itself rather than a direct drug effect on reproductive hormones.

Related

Guides:

• Cheapest GLP-1 Online · Insurance Coverage · Side Effects
• Mounjaro Dosage Guide · Oral vs Injectable · Exercise and Muscle
• Fat Loss vs Weight Loss · DEXA Scan Results · Mounjaro Plateau · Medicare Coverage · Wegovy Pill vs Injection

Provider Reviews: Ro · Hims · MEDVi · Found · Calibrate

Compare: All Providers · Best GLP-1 Programs · All Guides